UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection in China. The integrase strand transfer inhibitor (INSTI) was approved in May of last year for pre-exposure prophylaxis (PrEP) of HIV-1 in adults and adolescents (weighing ≥ 35kg) at risk of infection, to reduce the risk of sexually transmitted infections of HIV-1.
Dosage and Administration
Cabotegravir injection requires administration at least six times a year to achieve HIV pre-exposure prevention. Users will receive an initial injection of 600mg (3ml) per month for the first two months, followed by subsequent injections of 600mg (3ml) every two months. This regimen ensures continuous protection against HIV-1 infection.
Significance of the Launch
Cabotegravir injection is the first and only long-acting injection approved in China for HIV PrEP. This approval marks a significant advancement in the prevention of HIV-1, offering a convenient and effective option for individuals at risk of infection. The launch of cabotegravir injection underscores GSK’s commitment to improving public health and reducing the spread of HIV-1.-Fineline Info & Tech
